• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

    2/14/22 1:19:15 PM ET
    $CFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CFRX alert in real time by email
    SC 13G/A 1 cfrx56.htm

    OMB APPROVAL

    OMB Number: 3235-0145

    Estimated average burden hours per response ….11

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 7*)

    CONTRAFECT CORPORATION

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    212326102

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
      Rule 13d-1(c)
      Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

     
     

     

    .CUSIP No.: 212326102

    1. Names of Reporting Persons.
      I.R.S. Identification Nos. of above persons (entities only
      Federated Hermes, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 7,297,188
    6. Shared Voting Power
    7. Sole Dispositive Power: 7,297,188
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 7,297,188
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9): 18.55%
    12. Type of Reporting Person (See Instructions):HC

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only).
      Voting Shares Irrevocable Trust
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 7,297,188
    6. Shared Voting Power
    7. Sole Dispositive Power: 7,297,188
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 7,297,188
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9): 18.55%
    12. Type of Reporting Person (See Instructions):OO

     

    1. Names of Reporting Persons.
      I.R.S. Identification Nos. of above persons (entities only).
      Thomas R. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:  7,297,188
    7. Sole Dispositive Power
    8. Shared Dispositive Power: 7,297,188

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 7,297,188
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9): 18.55%
    12. Type of Reporting Person (See Instructions):IN

     

    1. Names of Reporting Persons.
      I.R.S. Identification Nos. of above persons (entities only).
      Rhodora J. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:  7,297,188
    7. Sole Dispositive Power
    8. Shared Dispositive Power: 7,297,188

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 7,297,188
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9): 18.55%
    12. Type of Reporting Person (See Instructions):IN

     

     

    1. Names of Reporting Persons.
      I.R.S. Identification Nos. of above persons (entities only)
      J. Christopher Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:  7,297,188
    7. Sole Dispositive Power
    8. Shared Dispositive Power: 7,297,188

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 7,297,188
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9): 18.55%
    12. Type of Reporting Person (See Instructions):IN

     

    Item 1.

    (a) Name of Issuer
      CONTRAFECT CORPORATION
    (b) Address of Issuer’s Principal Executive Offices.
      28 Wells Avenue, 3rd Floor
      Yonkers, NY 10701

    Item 2.

    (a) Name of Person Filing
    (b) Address Of Principal Business Office or, if none, Residence
      1001 Liberty Avenue, Pittsburgh, PA 15222-3779
    (c) Citizenship
    (d) Title of Class of Securities
       
    (e) CUSIP Number: 212326102
    Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
    (f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
    (g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    A. Federated Hermes, Inc.
    (a) Amount beneficially owned:  7,297,188
    (b) Percent of class:  18.55%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote: 7,297,188
      (ii) Shared power to vote or to direct the vote-0-
      (iii) Sole power to dispose or to direct the disposition of: 7,297,188
      (iv) Shared power to dispose or to direct the disposition of-0-

     

    B. Voting Shares Irrevocable Trust
    (a) Amount beneficially owned:  7,297,188
    (b) Percent of class:  18.55%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote: 7,297,188
      (ii) Shared power to vote or to direct the vote-0-
      (iii) Sole power to dispose or to direct the disposition of: 7,297,188
      (iv) Shared power to dispose or to direct the disposition of-0-

     

     

    C. Thomas R. Donahue
    (a) Amount beneficially owned:  7,297,188
    (b) Percent of class:  18.55%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:-0-
      (ii) Shared power to vote or to direct the vote: 7,297,188
      (iii) Sole power to dispose or to direct the disposition of:-0-
      (iv) Shared power to dispose or to direct the disposition of: 7,297,188

     

    D. Rhodora J. Donahue
    (a) Amount beneficially owned:  7,297,188
    (b) Percent of class:  18.55%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:-0-
      (ii) Shared power to vote or to direct the vote: 7,297,188
      (iii) Sole power to dispose or to direct the disposition of:-0-
      (iv) Shared power to dispose or to direct the disposition of: 7,297,188

     

    E. J. Christopher Donahue
    (a) Amount beneficially owned:  7,297,188
    (b) Percent of class:  18.55%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:-0-
      (ii) Shared power to vote or to direct the vote: 7,297,188
      (iii) Sole power to dispose or to direct the disposition of:-0-
      (iv) Shared power to dispose or to direct the disposition of: 7,297,188

     

    Instruction: Dissolution of a group requires a response to this item.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

    Instruction: Dissolution of a group requires a response to this item.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
    Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
    Item 9.Notice of Dissolution of Group: NOT APPLICABLE
    Item 10.Certification
    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
    (b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 10, 2022
    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    Date: February 10, 2022
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue individually and as Trust of Voting Shares Irrevocable Trust
       
    Date: February 10, 2022
    By: /s/Rhodora J. Donahue
    Name/Title: Rhodora J. Donahue, individually and as Trust of Voting Shares Irrevocable Trust, by J. Christopher Donahue, as attorney-in-fact
       
    Date: February 10, 2022
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trust of Voting Shares Irrevocable Trust
       

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

     
     

     

    EXHIBIT “1”

    ITEM 3 CLASSIFICATION OF REPORTING PERSONS

    Identity and Classification of Each Reporting Person

     

    IDENTITY CLASSIFICATION UNDER ITEM 3
    Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Hermes Insurance Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Equity Management Company of Pennsylvania (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Hermes, Inc. (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)
    FII Holdings, Inc. (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)
    Voting Shares Irrevocable Trust (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)
    Thomas R. Donahue (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)
    Rhodora J. Donahue (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)
    J. Christopher Donahue (g) parent Holding Company, in accordance with Section 240.13d-1(b)(ii)(G)

    Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the “Investment Advisers”), which act as investment advisers to registered investment companies and separate accounts that own shares of common stock in CONTRAFECT CORPORATION (the “Reported Securities”). The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue, Rhodora J. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

     
     

    EXHIBIT “2”

    AGREEMENT FOR JOINT FILING OF

    SCHEDULE 13G

    The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

    1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

    Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

    Thoms R. Donahue, individually and as Trustee

    Rhodora J. Donahue, individually and as Trustee

    J. Christopher Donahue, individually and as Trustee

    It is understood and agreed that each of the arties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

    It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

    Date: February 10, 2022

    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
       
    By: /s/Rhodora J. Donahue
    Name/Title: Rhodora J. Donahue, individually and as Trustee as Voting Shares Irrevocable Trust, by J. Christopher Donahue, as attorney-in-fact.
       
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

    1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue, Rhodora J Donahue, and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

     
     

     

    EXHIBIT “3”

    EXHIBIT “3”

     

    Get the next $CFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFRX

    DatePrice TargetRatingAnalyst
    7/14/2022$1.00Outperform → Mkt Perform
    SVB Leerink
    7/14/2022$15.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    2/16/2022$14.00 → $9.00Outperform
    SVB Leerink
    2/2/2022$6.50Speculative Buy → Buy
    WBB Securities
    9/9/2021$14.00Outperform
    SVB Leerink
    More analyst ratings

    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ContraFect downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00

      7/14/22 7:16:02 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously

      7/14/22 7:15:41 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on ContraFect with a new price target

      SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously

      2/16/22 5:18:49 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Messinger Michael

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      2/16/23 8:09:36 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Barlow Jane F

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:12:43 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sucoff Cary

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:03:32 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

      YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of

      10/16/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

      YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap

      9/19/23 8:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

      YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h

      9/18/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      2/14/24 2:24:05 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ContraFect Corporation

      SC 13G - CONTRAFECT Corp (0001478069) (Subject)

      2/14/23 12:22:09 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      9/9/22 11:03:32 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer

      Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress

      8/9/21 8:00:00 AM ET
      $CFRX
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

      YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i

      6/17/21 7:31:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ContraFect Corporation

      25-NSE - CONTRAFECT Corp (0001478069) (Subject)

      12/27/23 9:01:56 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - CONTRAFECT Corp (0001478069) (Filer)

      11/15/23 4:41:00 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ContraFect Corporation

      10-Q - CONTRAFECT Corp (0001478069) (Filer)

      11/14/23 4:00:30 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care